Abstract
Atherosclerosis is the major cause of cardiovascular morbidity and mortality. A multitude of pro-atherogenic mediators are known liable for the initiation and progression of atherogenic vascular lesions. Only few endogenous molecules are known so far with cardiovascular protective properties, whereas high-density lipoprotein (HDL) is one of the most important. Beside cholesterol efflux, many pleiotropic cell-mediated functions of HDL are known so far. HDL is a spherical particle that contains different proteins and lipids. Especially sphingolipids, like sphingosine-1-phosphate (S1P), has gained great attention. The HDL associated S1P seems to be responsible for many of the pleiotropic effects of HDL by activating special S1P receptors. This review focuses on HDL associated sphingolipids as mediators of known protective pleiotropic effects of HDL and their possible therapeutic relevance.
Keywords: High-density lipoprotein, sphingosine-1-phosphate, pleiotropic effects, sphingosine-1-phosphate receptors, endothelium
Current Pharmaceutical Design
Title: Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Volume: 16 Issue: 13
Author(s): Markus Tolle, Mirjam Schuchardt and Markus van der Giet
Affiliation:
Keywords: High-density lipoprotein, sphingosine-1-phosphate, pleiotropic effects, sphingosine-1-phosphate receptors, endothelium
Abstract: Atherosclerosis is the major cause of cardiovascular morbidity and mortality. A multitude of pro-atherogenic mediators are known liable for the initiation and progression of atherogenic vascular lesions. Only few endogenous molecules are known so far with cardiovascular protective properties, whereas high-density lipoprotein (HDL) is one of the most important. Beside cholesterol efflux, many pleiotropic cell-mediated functions of HDL are known so far. HDL is a spherical particle that contains different proteins and lipids. Especially sphingolipids, like sphingosine-1-phosphate (S1P), has gained great attention. The HDL associated S1P seems to be responsible for many of the pleiotropic effects of HDL by activating special S1P receptors. This review focuses on HDL associated sphingolipids as mediators of known protective pleiotropic effects of HDL and their possible therapeutic relevance.
Export Options
About this article
Cite this article as:
Tolle Markus, Schuchardt Mirjam and van der Giet Markus, Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins, Current Pharmaceutical Design 2010; 16 (13) . https://dx.doi.org/10.2174/138161210791050979
DOI https://dx.doi.org/10.2174/138161210791050979 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Effects of the Antidiabetic Drugs on the Age-Related Atrophy and Sarcopenia Associated with Diabetes Type II.
Current Diabetes Reviews Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Current Medicinal Chemistry The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Streptozotocin-Induced Diabetes Mellitus in Neonatal Rats: An Insight into its Applications to Induce Diabetic Complications
Current Diabetes Reviews Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Mechanical Circulatory Support for End-Stage Heart Failure in Repaired and Palliated Congenital Heart Disease
Current Cardiology Reviews Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Thymosin β4 Protein Therapy for Cardiac Repair
Current Pharmaceutical Design Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Molecular Modeling Investigation of Some New 2-mercaptoimidazoles
Current Computer-Aided Drug Design